Merck Sharp + Dohme Corp.

Chakravarthy Nachu Narasimhan

Ramesh Kashi

Manoj K Sharma

Paul Reichert

Peter Orth

Winifred W Prosise

Mohammed Shameem

Sarita Mittal

Ashwin Basarkar

Soumendu Bhattacharya

Yogita Krishnamachari

Kevin James Gergich

Soonmo Peter Kang

Wendy Benjamin

The invention relates to stable formulations of antibodies against human programmed death receptor PD-1, or antigen binding fragments thereof. In some embodiments the formulations of the invention comprise between 5-200 mg/mL anti-PD-1 antibody, or antigen binding fragment thereof. The invention further provides methods for treating various cancers with stable formulations of the invention. In some embodiments of the methods of the invention, the formulations are administered to a subject by intravenous or subcutaneous administration.

Stable formulations of programmed death receptor 1 (PD-1) antibodies and methods of use thereof

Crystalline forms of antibodies to human IL-23, such as antibodies to human IL-23p19 , are provided, as well as methods of producing such crystalline forms, and uses of such crystalline forms, e.g. in treatment of inflammatory, autoimmune, and proliferative disorders. In various embodiments, the anti-hulL-23 antibody crystals, such as anti-hulL-23p19 antibody crystals of the present invention are obtainable by batch crystallization methods, vapor diffusion methods, liquid-liquid diffusion methods, and dialysis. In other aspects, the invention relates to suspensions of the crystalline anti-hulL-23 antibodies of the present invention, including those at higher concentrations and lower viscosities than would be possible with a corresponding non-crystalline solution at the same concentration of antibody. In other embodiments, the anti-huiL-23 antibody crystals of the present invention have increased stability, i.e. they maintain biological activity of the anti-huiL-23 antibody, such as anti-huiL-23p 19 antibody, longer than corresponding solution formulations.

Crystalline anti-human IL-23p19 antibodies

The present invention relates to stable formulations of antibodies against human programmed death receptor PD-1, or antigen binding fragments thereof. The present invention further provides methods for treating various cancers and chronic infections with stable formulations of antibodies against human programmed death receptor PD-1, or antigen binding fragments thereof.

Stable formulations of antibodies to human programmed death receptor PD-1 and related treatments

Growing community of inventors

Scotch Plains, NJ, United States of America

Chakravarthy Nachu Narasimhan